Alex Golts, Daniel Khapun, et al.
MICCAI 2021
For nearly 40 years, drug dossiers have supported the quality, safety and risk/benefits of medicinal products - essentially becoming the passport that every drug requires to enter the market. However, because of changing market conditions and the increasing policy of cost-containment, a good drug dossier, with its duly compiled quality, safety and efficacy reports, is no longer sufficient. Thus the traditional drug dossier will soon be replaced some day by compounded e-documents, submitted in XML format, reviewed and approved on-line by the regulators, under the scrutiny of patient groups and with the final blessing of governmental and private payers.
Alex Golts, Daniel Khapun, et al.
MICCAI 2021
Victor W. L. Ng, Julian M. W. Chan, et al.
Advanced Drug Delivery Reviews
Niamh Aspell, Abigail Goldsteen, et al.
Frontiers in Digital Health
Joshua Hui, Sarah Knoop, et al.
IHI 2012